Aptose Biosciences Secures Final Court Approval for Hanmi Acquisition, Reports Positive Clinical Data
Summary
Aptose Biosciences received final court approval for its acquisition by Hanmi Pharmaceutical, providing a cash exit for shareholders and a resolution for the financially distressed company, alongside positive clinical trial results.
Key Events
-
Final Court Approval for Acquisition
The Court of King's Bench of Alberta issued a final order approving the plan of arrangement for Hanmi Pharmaceutical to acquire all outstanding common shares of Aptose.
-
Shareholder Approval Confirmed
Shareholders approved the 'Go Private' transaction, where they will receive C$2.41 in cash per share, representing a 28% premium over the 30-day volume-weighted average price (VWAP).
-
Positive Clinical Data Reported
The company presented promising safety and efficacy data for its tuspetinib (TUS+VEN+AZA) triplet therapy in newly diagnosed AML patients, demonstrating high response rates and MRD negativity.
-
Acquisition Expected by April 2026
The transaction is anticipated to close by the end of April 2026, pending customary closing and regulatory approvals.
Analysis
This 8-K, through its attached press release, confirms the final court approval for Aptose Biosciences' acquisition by Hanmi Pharmaceutical, following shareholder approval. This definitive step provides a cash exit for shareholders at C$2.41 per share, offering a resolution for the financially distressed company. The filing also includes positive clinical data for tuspetinib, highlighting its efficacy in AML patients, which supports the underlying value of the acquired asset. The acquisition is expected to close by the end of April 2026, subject to regulatory approvals.
At the time of this filing, APTOF was trading at $1.67 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.64 to $4.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.